Athletes and doping: Effects of drugs on the respiratory system

Thorax

Volumn 54, Issue 11, 1999, Pages 1041-1046

  Dekhuijzen, P N R ^a   Machiels, H A ^a   Heunks, L M A ^a   Van Der Heijden, H F M ^a   Van Balkom, R H H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMINOPHYLLINE; AMPHETAMINE; ANABOLIC AGENT; ANTIHISTAMINIC AGENT; ANTITUSSIVE AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CAFFEINE; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLENBUTEROL; CORTICOSTEROID; CROMOGLYCATE DISODIUM; EPHEDRINE; EXPECTORANT AGENT; FENOTEROL; GLYCOPROTEIN; HUMAN GROWTH HORMONE; METHYLXANTHINE; NARCOTIC AGENT; PEPTIDE HORMONE; PHENYLPROPANOLAMINE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHLETE; DOPING; DRUG LEGISLATION; EXERCISE INDUCED ASTHMA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL ETHICS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESPIRATORY FUNCTION; REVIEW;

EID: 0032699472     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.11.1041     Document Type: Review

References (90)

1. International Olympic Committee. List of classes of prohibited substances and methods of doping. 1999.
2. Dempsey JA. J. B. Wolffe memorial lecture. Is the lung built for exercise? Med Sci Sports Exerc 1986;18:143-55.
3. di Prampero PE, Ferretti G. Factors limiting maximal oxygen consumption in humans. Respir Physiol 1990;80:113-27.
4. Dempsey JA, Hanson PG, Henderson KS. Exercise-induced arterial hypoxaemia in healthy human subjects at sea level. J Physiol Lond 1984;355:161-75.
5. Williams JH, Powers SK, Stuart MK. Hemoglobin desaturation in highly trained athletes during heavy exercise. Med Sci Sports Exerc 1986;18:168-73.
6. Leith DE, Bradley M. Ventilatory muscle strength and endurance training. J Appl Physiol 1976;41:508-16.
7. Bai TR, Rabinovitch J, Pardy RL. Near-maximal voluntary hyperpnea and ventilatory muscle function. J Appl Physiol 1984;57:1742-8.
8. Bye PT, Farkas GA, Roussos C. Respiratory factors limiting exercise. Annu Rev Physiol 1983;45:439-51.
9. Loke J, Mahler DA, Virgulto JA. Respiratory muscle fatigue after marathon running. J Appl Physiol 1982;52:821-4.
10. Bye PT, Esau SA, Walley KR, et al. Ventilatory muscles during exercise in air and oxygen in normal men. J Appl Physiol 1984;56:464-71.
11. Martin B, Heintzelman M, Chen HI. Exercise performance after ventilatory work. J Appl Physiol 1982;52:1581-5.
12. Boutellier U, Piwko P. The respiratory system as an exercise limiting factor in normal sedentary subjects. Eur J Appl Physiol 1992;64:145-52.
13. 2max and maximal ventilation. Eur J Appl Physiol 1982;49:379-87.
14. Casaburi R, Storer TW, Wasserman K. Mediation of reduced ventilatory response to exercise after endurance training. J Appl Physiol 1987;63:1533-8.
15. Morgan DW, Kohrt WM, Bates BJ, et al. Effects of respiratory muscle endurance training on ventilatory and endurance performance of moderately trained cyclists. Int J Sports Med 1987;8:88-93.
16. Fairbarn MS, Coutts KC, Pardy RL, et al. Improved respiratory muscle endurance of highly trained cyclists and the effects on maximal exercise performance. Int J Sports Med 1991;12:66-70.
17. Hanel B, Secher NH. Maximal oxygen uptake and work capacity after inspiratory muscle training: a controlled study. J Sports Sci 1991;9:43-52.
18. Boutellier U, Buchel R, Kundert A, et al. The respiratory system as an exercise limiting factor in normal trained subjects. Eur J Appl Physiol 1992;65:347-53.
19. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathicomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, eds. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996; 199-237.
20. Clarkson PM, Thompson HS. Drugs and sport. Research findings and limitations. Sports Med 1997;24:366-84.
21. Folgering H. Studying the control of breathing in man. Eur Respir J 1988;1:651-60.
22. Pinter EJ, Pattee CJ. Fat-mobilizing action of amphetamine. J Clin Invest 1968;47:394-402.
23. Chandler JV, Blair SN. The effect of amphetamines on selected physiological components related to athletic success. Med Sci Sports Exerc 1980;12:65-9.
24. Cuthbertson DP, Knox JAC. The effects of analeptics on the fatigued subject. J Physiol 1947;106:42-58.
25. Smith GM, Beecher HK. Amphetamine, secobarbital, and athletic performance. JAMA 1960;172:1502-14.
26. Karpovich PV. Effect of amphetamine sulfate on athletic performance. JAMA 1959;170:558-61.
27. Dollery C. Therapeutic Drugs. Edinburgh: Churchill Living-stone, 1999.
28. D'Urzo AD, Jhirad R, Jenne H, et al. Effect of caffeine on ventilatory responses to hypercapnia, hypoxia, and exercise in humans. J Appl Physiol 1990;68:322-8.
29. Supinski GS, Levin S, Kelsen SG. Caffeine effect on respiratory muscle endurance and sense of effort during loaded breathing. J Appl Physiol 1986;60:2040-7.
30. +] in humans. J Appl Physiol 1993;74:1149-55.
31. 0 on membrane potential and contraction in mouse fast- and slow-twitch muscle. Am J Physiol 1997;273:C598-611.
32. Hultman E. Nutritional effects on work performance. Am J Clin Nutr 1989;49:949-57.
33. Spriet LL, MacLean DA, Dyck DJ, et al. Caffeine ingestion and muscle metabolism during prolonged exercise in humans. Am J Physiol 1992;262:E891-8.
34. Cheetham ME, Boobis LH, Brooks S, et al. Human muscle metabolism during sprint running. J Appl Physiol 1986;61:54-60.
35. Jackman M, Wendling P, Friars D, et al. Metabolic catecholamine and endurance responses to caffeine during intense exercise. J Appl Physiol 1996;81:1658-63.
36. Green HJ, Ball Burnett ME, Morrissey MA, et al. Fiber type specific glycogen utilization in rat diaphragm during treadmill exercise. J Appl Physiol 1987;63:75-83.
37. Haldi H, Wynn W. Action of drugs on efficiency of swimmers. Res Q Exerc Sport 1946;17:17-96.
38. Lanigan C, Howes TQ, Borzone G, et al. The effects of beta 2-agonists and caffeine on respiratory and limb muscle performance. Eur Respir J 1993;6:1192-6.
39. Wemple RD, Lamb DR, McKeever KH. Caffeine vs caffeine-free sports drinks: effects on urine production at rest and during prolonged exercise. Int J Sports Med 1997;18:40-6.
40. Bell DG, Jacobs I, Zamecnik J. Effects of caffeine, ephedrine and their combination on time to exhaustion during high-intensity exercise. Eur J Appl Physiol 1998;77:427-33.
41. Bright TP, Sandage BW Jr, Fletcher HP. Selected cardiac and metabolic responses to pseudoephedrine with exercise. J Clin Pharmacol 1981;21:488-92.
42. Clemons JM, Crosby SL. Cardiopulmonary and subjective effects of a 60 mg dose of pseudoephedrine on graded treadmill exercise. J Sports Med Phys Fitness 1993;33:405-12.
43. Gillies H, Derman WE, Noakes TD, et al. Pseudoephedrine is without ergogenic effects during prolonged exercise. J Appl Physiol 1996;81:2611-7.
44. Saux MC, Girault J, Bouquet S, et al. Comparative study of the tissue distribution of two beta-mimetics: clenbuterol and salbutamol in the dog. J Pharmacol 1986; 17:692-8.
45. Caccia S, Fong MH. Kinetics and distribution of the beta-adrenergic agonist salbutamol in rat brain. J Pharm Pharmacol 1984;36:200-2.
46. Caruso JF, Signorile JF, Perry AC, et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc 1995;27:1471-6.
47. 2-agonists on improving exercise tolerance in patients with reversible chronic airway obstruction. Respiration 1996;63:8-16.
48. Maltin CA, Delday MI, Watson JS, et al. Clenbuterol, a β-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci 1993;84:651-4.
49. 2-adrenoreceptor agonist, increases skeletal muscle strength in young men. Clin Sci 1992;83:615-21.
50. Violante B, Pellegrino R, Vinay C et al. Failure of aminophylline and salbutamol to improve respiratory muscle function and exercise tolerance in healthy humans. Respiration 1989;55:227-36.
51. van der Heijden HFM, Dekhuijzen PNR, Folgering HTM, et al. Pharmacotherapy of respiratory muscles in chronic obstructive pulmonary disease. Respir Med 1996;90:513-22.
52. Freeman W, Packe GE, Cayton RM. Effect of nebulised salbutamol on maximal exercise performance in men with mild asthma. Thorax 1989;44:942-7.
53. Lemmer JT, Fleck SJ, Wallach JM, et al. The effects of albuterol on power output in non-asthmatic athletes. Int J Sports Med 1995;16:243-9.
54. McDowell SL, Fleck SJ, Storms WW. The effects of salmeterol on power output in nonasthmatic athletes. J Allergy Clin Immunol 1997;99:443-9.
55. Mccuwisse WH, McKenzie DC, Hopkins SR, et al. The effect of salbutamol on performance in elite nonasthmatic athletes. Med Sci Sports Exerc 1992;24:1161-6.
56. Morton AR, Joyce K, Papalia SM, et al. Is salmeterol ergogenic? Clin J Sport Med 1996;6:220-5.
57. Morton AR, Papalia SM, Fitch KD. Is salbutamol ergogenic? The effects of salbutamol on physical performance in high-performance nonasthmatic athletes. Clin J Sport Med 1992;2:93-7.
58. Norris SR, Petersen SR, Jones RL. The effect of salbutamol on performance in endurance cyclists. Eur J Appl Physiol 1996;73:364-8.
59. 2-adrenoceptor agonist salmeterol are dependent on route of administration. Am J Physiol 1994;267:E475-84.
60. 2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep 1984;4:83-91.
61. 2-adrenoceptor activation. Am J Physiol 1992;263:E50-6.
62. Reeds PJ, Hay SM, Dorwood PM, et al. Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. Br J Nutr 1986;56:249-58.
63. Hall IP, Woodhead MA, Johnston IDA. Effect of high-dose salbutamol on cardiac rhythm in severe chronic airflow obstruction: a controlled study. Respiration 1994;61:214-8.
64. Reeds PJ, Hay SM, Dorward PM, et al. The effect of β-agonists and antagonists on muscle growth and body composition of young rats (Rattus sp.). Comp Biochem Physiol 1988;89C:337-41.
65. 24 regulation in skeletal myotubes. Am J Physiol 1999;276:C1038-45.
66. van der Heijden HFM, Dekhuijzen PNR, Folgering H, et al. Long-term effects of clenbuterol on diaphragm morphology and contractile properties in emphysematous hamsters. J Appl Physiol 1998;85:215-22.
67. van der Heijden HFM, Dekhuijzen PNR, Folgering H, et al. Inotropic effects of salbutamol on rat diaphragm contractility are potentiated by foreshortening. Am J Respir Crit Care Med 1997;155:1072-9.
68. 2-Adrenoceptor agonists reduce the decline of rat diaphragm twitch force during severe hypoxia. Am J Physiol 1999;276:L474-80.
69. van der Heijden HFM, van Balkom RHH, Folgering HTM, et al. Effects of salbutamol on rat diaphragm contractility. J Appl Physiol 1996;81:1103-10.
70. van der Heijden HFM, Zhan WZ, Prakash YS, et al. Salbutamol enhances isotonic contractile properties of rat diaphragm muscle. J Appl Physiol 1998;85:525-9.
71. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984;12:469-84.
72. Lewis MI, Fournier M, Yeh AY, et al. Alteration in diaphragm contractility after nandrolone administration: an analysis of potential mechanisms. J Appl Physiol 1999;86:985-92.
73. Beiner JM, Jokl P, Cholewicki J, et al. The effect of anabolic steroids and corticosteroids on healing of muscle contusion injury. Am J Sports Med 1999;27:2-9.
74. Schols AMWJ, Soeters PB, Mostert R, et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: a placebo-controlled randomized trial. Am J Respir Crit Care Med 1995;152:1268-74.
75. Sprungen AM, Grimm D, Dumitrescu O, et al. Improvements in diaphragm width and pulmonary function following anabolic steroid therapy in subjects with tetraplegia. Am J Respir Crit Care Med 1999;159:A586.
76. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1-7.
77. Hervey GR, Hutchinson I, Knibbs AV, et al. "Anabolic" effects of methandienone in men undergoing athletic training. Lancet 1976;ii:699-702.
78. Johnson LC, Roundy ES, Allsen PE, et al. Effect of anabolic steroid treatment on endurance. Med Sci Sports 1975;7:287-9.
79. Freed DLJ, Banks AJ, Longson D, et al. Anabolic steroids in athelics: crossover double-blind trial on weightlifters. BMJ 1975;2:471-3.
80. Hervey GR, Knibbs AV, Burkinshaw L, et al. Effects of methandienone on the performance and body composition of men undergoing athletic training. Clin Sci 1981;60:457-61.
81. Clarkson PM, Thompson HS. Drugs and sport. Research findings and limitations. Sports Med 1997;24:366-84.
82. Yarasheski KE. Growth hormone effects on metabolism, body composition, muscle mass, and strength. Exerc Sport Sci Rev 1994;22: 285-312.
83. Crist DM, Peake GT, Egan PA, et al. Body composition response to exogenous GH during training in highly conditioned adults. J Appl Physiol 1988;65:579-84.
84. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
85. Salomon F, Cuneo RC, Hesp R, et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797-803.
86. Wagner JC. Enhancement of athletic performance with drugs. An overview. Sports Med. 1991;12:250-65.
87. Deyssig R, Frisch H, Blum WF, et al. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol Copenh 1993;128:313-8.
88. Yarasheski KE, Campbell JA, Smith K, et al. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol 1992;262:E261-7.
89. Yarasheski KE, Zachwieja JJ, Campbell JA, et al. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol 1995;268:E268-76.
90. Yarasheski KE, Zachweija JJ, Angelopoulos TJ, et al. Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J Appl Physiol 1993;74:3073-6.